Assenagon Asset Management S.A. Buys 2,285 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Assenagon Asset Management S.A. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 13.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,918 shares of the biopharmaceutical company’s stock after acquiring an additional 2,285 shares during the period. Assenagon Asset Management S.A.’s holdings in Alnylam Pharmaceuticals were worth $4,687,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of ALNY. Huntington National Bank increased its stake in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth $29,000. Washington Trust Advisors Inc. bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth $42,000. True Wealth Design LLC grew its position in shares of Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 153 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $45,000. Institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the sale, the chief executive officer now owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the sale, the chief marketing officer now owns 17,457 shares of the company’s stock, valued at approximately $4,381,357.86. This trade represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,122 shares of company stock valued at $2,540,455. 1.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ALNY has been the topic of a number of analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, January 13th. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Sanford C. Bernstein cut their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Finally, Piper Sandler reissued an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $298.61.

Get Our Latest Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Stock Down 1.2 %

ALNY opened at $246.27 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a market cap of $31.76 billion, a PE ratio of -94.00 and a beta of 0.34. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The company has a 50 day moving average of $245.95 and a 200 day moving average of $259.84.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same period in the previous year, the business posted $1.15 EPS. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Alnylam Pharmaceuticals Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

See Also

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.